Cargando…
A Polypeptide of Tumor-Associated Antigen L6 with Intrinsic Adjuvant Activity Enhances Antitumor Immunity
Peptide vaccines are safe, and aim to elicit and expand tumor-specific immunity so as to eradicate tumors. However, achieving strong and long-lasting anti-tumor immunity with peptide vaccines for the antigen-specific treatment of cancer is challenging, in part because their efficacy depends on stron...
Autores principales: | Sher, Yuh-Pyng, Chai, Kit Man, Chen, Wen-Ching, Shen, Kuan-Yin, Chen, I-Hua, Lee, Ming-Hui, Chiu, Fang-Feng, Liu, Shih-Jen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711899/ https://www.ncbi.nlm.nih.gov/pubmed/33096846 http://dx.doi.org/10.3390/vaccines8040620 |
Ejemplares similares
-
Immunological evaluation of a novel HLA-A2 restricted phosphopeptide of tumor associated Antigen, TRAP1, on cancer therapy
por: Lin, Min-Han, et al.
Publicado: (2019) -
A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population
por: Wu, Chiao-Chieh, et al.
Publicado: (2016) -
Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment
por: Yan, Wan-Lun, et al.
Publicado: (2021) -
Antitumor effect and mechanism of FZD7 polypeptide vaccine
por: Hua, Zhongke, et al.
Publicado: (2022) -
A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine
por: Tzeng, Tsai-Teng, et al.
Publicado: (2023)